PL2468861T3 - Sposób konstruowania nośnika do przenoszenia genów - Google Patents

Sposób konstruowania nośnika do przenoszenia genów

Info

Publication number
PL2468861T3
PL2468861T3 PL12151228T PL12151228T PL2468861T3 PL 2468861 T3 PL2468861 T3 PL 2468861T3 PL 12151228 T PL12151228 T PL 12151228T PL 12151228 T PL12151228 T PL 12151228T PL 2468861 T3 PL2468861 T3 PL 2468861T3
Authority
PL
Poland
Prior art keywords
transport support
gene transport
constructing gene
constructing
support
Prior art date
Application number
PL12151228T
Other languages
English (en)
Inventor
Yuko Shimatani
Yoshinori Hamaji
Hitomi Shimizu
Jun Amano
Shun'ichiro Taniguchi
Minoru Fujimori
Original Assignee
Anaeropharma Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science Inc filed Critical Anaeropharma Science Inc
Publication of PL2468861T3 publication Critical patent/PL2468861T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL12151228T 2006-05-24 2007-05-24 Sposób konstruowania nośnika do przenoszenia genów PL2468861T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006144720 2006-05-24
EP12151228.9A EP2468861B1 (en) 2006-05-24 2007-05-24 Method of constructing gene transport support
EP07744005A EP2019138A4 (en) 2006-05-24 2007-05-24 METHOD FOR CONSTRUCTING A GENE TRANSPORT MEDIUM

Publications (1)

Publication Number Publication Date
PL2468861T3 true PL2468861T3 (pl) 2015-03-31

Family

ID=38723416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12151228T PL2468861T3 (pl) 2006-05-24 2007-05-24 Sposób konstruowania nośnika do przenoszenia genów

Country Status (12)

Country Link
US (1) US8911721B2 (pl)
EP (2) EP2019138A4 (pl)
JP (1) JP5048661B2 (pl)
KR (1) KR101407975B1 (pl)
CN (2) CN102747074B (pl)
CA (1) CA2652689C (pl)
DK (1) DK2468861T3 (pl)
ES (1) ES2525174T3 (pl)
PL (1) PL2468861T3 (pl)
PT (1) PT2468861E (pl)
SG (1) SG172610A1 (pl)
WO (1) WO2007136107A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535939B2 (en) 2010-01-29 2013-09-17 Anaeropharma Science, Inc. Transfection vector
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
PL2274422T3 (pl) 2008-04-17 2017-09-29 Anaeropharma Science, Inc. Wektor ekspresyjny
DE102009017908A1 (de) * 2009-04-17 2010-10-21 Kist-Europe Forschungsgesellschaft Mbh Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
JPWO2013008881A1 (ja) 2011-07-13 2015-02-23 株式会社アネロファーマ・サイエンス 虚血性疾患治療薬
CA2974333C (en) 2015-01-19 2018-09-25 Shinshu University Therapeutic agent for ischemic disease
CN111249222B (zh) * 2020-03-02 2022-08-26 郑州大学 一种由细菌驱动的生物马达联合递药系统的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
CN1281894A (zh) * 1999-07-23 2001-01-31 中国人民解放军第二军医大学南京军医学院 转人内皮抑素(Endostatin)基因乳酸菌的方法、产品及其应用
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
US8021653B2 (en) * 2004-11-24 2011-09-20 Anaeropharma Science Inc. Shuttle vector for Bifidobacterium and Escherichia coli
EP1867714B1 (en) 2005-04-08 2013-09-18 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof

Also Published As

Publication number Publication date
US8911721B2 (en) 2014-12-16
EP2468861B1 (en) 2014-09-10
KR101407975B1 (ko) 2014-06-17
KR20090023350A (ko) 2009-03-04
JPWO2007136107A1 (ja) 2009-10-01
DK2468861T3 (en) 2014-12-08
CN101448940A (zh) 2009-06-03
ES2525174T3 (es) 2014-12-18
CA2652689C (en) 2016-02-23
US20090169516A1 (en) 2009-07-02
PT2468861E (pt) 2014-12-05
SG172610A1 (en) 2011-07-28
CN102747074A (zh) 2012-10-24
CN102747074B (zh) 2014-06-25
EP2468861A1 (en) 2012-06-27
EP2019138A4 (en) 2009-12-09
JP5048661B2 (ja) 2012-10-17
CA2652689A1 (en) 2007-11-29
EP2019138A1 (en) 2009-01-28
WO2007136107A1 (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
EP2172547A4 (en) PROCESS FOR EXPRESSING A SPECIFIC GENE
EP2050819A4 (en) NUCLEOTIDE-amplification
PL2168790T3 (pl) Konstrukcja podpierająca dla stabilizatora i sposób podpierania stabilizatora
EP2324131A4 (en) PROCESS FOR ISOLATING SMALL RNA
GB2449006B (en) System and method for interlocking support blocks
IL206606A (en) Gene expression systems and methods for their use
GB0609420D0 (en) Method of gene transfer
EP2058396A4 (en) nucleic acid amplification
PT2468861E (pt) Método de construção de suporte de tranporte de genes
HK1132974A1 (en) Transport unit and method of manufacture thereof
EP1953224A4 (en) CHROMOSOME MODIFICATION METHOD
EP2235905A4 (en) SYSTEM AND METHOD FOR MULTIPLE-TOPOLOGY SUPPORT
EP2018420A4 (en) IMPROVED GENE SILENCING METHODS
IL206799A (en) Support element for shell support and method
EP2193208A4 (en) DNA AMPLIFICATION METHOD
GB2446175B (en) Method of updating data
EP2195453A4 (en) METHOD FOR AMPLIFYING NUCLEIC ACID
EP2185706A4 (en) IMPROVED GEN-SILENCING PROCEDURES
GB0817384D0 (en) Method of providing location data
EP1935988A4 (en) METHOD AND SYSTEM FOR GENE EXPRESSION IMAGE FORMATION
PL2092051T3 (pl) Fermentor
GB2453210B (en) Biochip and method of fabrication
ZA200808672B (en) Bioreactor
EP1997896A4 (en) GENEIGNING AND LIGNAN METHYLATING ENZYME
EP1884570A4 (en) GENE TRANSFER METHOD